How are atorvastatin and pravastatin the same?
Both atorvastatin and pravastatin are statins. They lower LDL (“bad”) cholesterol by reducing cholesterol production in the liver and are used to treat high cholesterol and reduce cardiovascular risk in people who qualify for statin therapy.
What’s the key difference between them?
The main practical difference is that atorvastatin is metabolized more by the liver’s CYP3A4 pathway, while pravastatin relies much less on CYP metabolism. In practice, that can make atorvastatin more sensitive to drug-drug interactions with medications that inhibit or induce CYP3A4, while pravastatin typically has fewer CYP-related interactions.
Which statin tends to be stronger for lowering LDL?
Atorvastatin is generally considered more potent for LDL lowering than pravastatin on a dose-for-dose basis, though the exact response varies by person, dose, and treatment goals.
Do they differ in how they’re cleared and what that means for drug interactions?
Because of the CYP3A4 dependence, atorvastatin can interact with more common CYP3A4 modulators (for example, certain antibiotics/antifungals and some HIV/hepatitis medicines). Pravastatin’s lower CYP involvement often means fewer of these interaction concerns, which can matter when patients take multiple medications.
Are they taken differently or dosed differently?
They are both taken by mouth once daily, but typical dose ranges differ by medication. Clinicians adjust the dose to target LDL reduction and to fit safety considerations, including interaction risk.
What side effects are the same, and what should patients watch for?
Common statin side effects can include muscle aches and, rarely, more serious muscle injury, and liver enzyme elevations. The same core safety guidance applies to both: people should report unexplained muscle pain, weakness, or dark urine promptly, and clinicians may check liver enzymes and review interacting medicines.
Which one is often chosen when drug interactions are a concern?
When someone is on medications that are likely to interact through CYP3A4, clinicians often prefer a statin with a lower interaction profile, such as pravastatin, though the best choice depends on the patient’s cholesterol level, cardiovascular risk, kidney/liver status, and overall med list.